Citius pharmaceuticals expands scientific advisory board with addition of dr. john laffey, expert in stem cell and gene therapies for ards

Cranford, n.j., june 15, 2021 /prnewswire/ -- citius pharmaceuticals, inc. ("citius" or the "company") (nasdaq: ctxr), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on anti-infective products in adjunct cancer care, unique prescription products and stem cell therapy, today announced that dr. john laffey, a leading scholar in acute respiratory distress syndrome (ards) and the use of cutting-edge therapies to treat acute lung disorders, has been appointed to its ards scientific advisory board (sab), effective immediately.
CTXR Ratings Summary
CTXR Quant Ranking